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Editorial

Atypical PKC: therapeutic target for Alzheimer’s?
Robert V. Farese and Mini P. Sajan

retase, Aβ-peptides and phospho-tau are commensurately reduced in mice haploinsufficient for PKCλ (unpublished).
However, insulin is but one of many factors known to
activate aPKC. And, with respect to biological factors
thought to abet AD development when present in excess
or unduly activated, aPKCs are directly activated by
tumor necrosis factor-α, ceramides (and therefore precursor fatty acids and spingolipids), phosphatidic acid
(and therefore precursor fatty acids and glucose, and
activators of phospholipase D, e.g., superoxide H2O2),
and agents that, like insulin, activate tyrosine kinase
receptors and PI3K, e.g., BDNF, NGF and AMPA
receptor activators. This promiscuity of aPKC activation may provide a unifying mechanism whereby a wide
variety of AD risk factors may abet AD development.
It may seem surprising to suggest that insulin excess
serves as a risk factor for AD development, as it is
commonly assumed that the brain is insulin-resistant in
T2DM-associated AD, and the activity of the brain
insulin receptor (IR) is modestly diminished in nondiabetic AD [4], Furthermore, nasal insulin, now in
phase 3 clinical trials, is reportedly beneficial in some
patients [5]. Note, however, that the existing hyperinsulinemia in high-fat-fed obese/T2DM mice
markedly/fully increases brain IR activity, as well as
activities of aPKC and Akt [3]. Also note that maximal
activation of downstream processes are seen at submaximal levels of IR activation in most tissues (presumably in brain as well), i.e., there are “spare” IRs.
Thus, as long as insulin levels are sufficiently elevated
in insulin-resistant states, insulin may serve to increase
aPKC activity, β-secretase activity, and levels of Aβpeptides and phospho-tau. On the other hand, as insulin
levels decline in T2DM, the brain may become hypoinsulinized and insulin therapy may have beneficial
effects on apoptosis and various anabolic processes that
are mediated by Akt.
Accordingly, there may be distinct phases of T2DM
wherein the brain is hyper- or hypo-insulinized, and this
may be relevant to successes and failures of insulin
therapy in individual AD patients. Also, in normoinsulinemic non-diabetic AD, the observed decrease in
brain IR activity [4] most likely limits insulin action,
and insulin therapy may well be beneficial in these
patients. In this regard, note that, although brain IR
activity is mildly/modestly reduced in non-diabetic AD,

Dementias in the elderly are cruel and costly fates for
afflicted patients and their families. Present therapeutic
targets have had little success in preventing or treating
these disorders.
In Alzheimer’s Disease (AD) and other dementias, Aβ
plaques and phospho-tau tangles are the main pathological elements thought to impair neuronal functions of
memory and cognition, and ultimately compromise
neuronal integrity in the hippocampus and other critical
brain areas. β-secretase activation is thought to be a key
factor underlying the production of Aβ-peptide plaque
precursors. Indeed, knockout of β-secretase can curtail
AD development in transgenic mice harboring AD
mutations [1]. Thus, much effort has been put into the
development of effective and safe inhibitors of βsecretase, but, with limited success, there is a pressing
need to develop alternate strategies.
Relevant to this need, we recently found that insulin
acutely activated β-secretase and increased production
of Aβ-peptides and phospho-tau in brains of intact mice,
and in isolated neuronal cells and mouse hippocampal
slices [2,3]. Moreover, hyperinsulinemia in several
mouse and monkey models of insulin-resistant forms of
obesity and type 2 diabetes mellitus (T2DM) appeared
to be directly responsible for neuronal increases in βsecretase activity and levels of Aβ-peptides and
phospho-tau; as correction of hyperinsulinemia by liverdirected treatments reversed these CNS aberrations
[2,3]. These findings may help to explain how longstanding hyperinsulinemic states of obesity, the
metabolic syndrome and T2DM, which collectively
afflict over half of the over-fifty US population, may
abet AD development.
Importantly, we found that the activation of atypical
PKC (aPKC), PKC-λ/ι, rather than Akt [both protein
kinases are activated by phosphatidylinositol 3-kinase
(PI3K) during insulin action and mediate most insulin
effects] was responsible for insulin-induced increases in
β-secretase, Aβ-peptides and phospho-tau [2,3].
Perhaps more importantly, administration of aPKC
inhibitors that pass the BBB were able to not only block
acute insulin-dependent increases in β-secretase, Aβpeptides and phospho-tau, but also, in mouse models of
obesity and T2DM, simultaneously improve associated
memory impairments [2,3]. As further evidence for
aPKC importance, insulin-dependent increases in β-sec-
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the activities of aPKC and Akt are reportedly elevated
[4], suggesting (a) the activation of PI3K (and thus
aPKC and Akt) by non-insulin factors, and (b) that the
reduction of IR activity in non-diabetic AD is due to
well-recognized negative feedback inhibition of the IR
via activation of aPKC, Akt, and/or other signaling
factors, e.g., conventional PKCs, ERK and mTOR, that
can function downstream of PI3K. Thus, in non-diabetic
AD, whereas some elements of insulin action may be
diminished by IR impairment, aberrations mediated by
aPKC, may be excessive via action of non-insulin
activator. This combination of impaired IR activity and
elevated aPKC activity may benefit from a combination
of insulin and aPKC inhibitor therapy.
To summarize, aPKC hyperactivity in brain appears to
be present in both hyperinsulinemic phases of obesity
and T2DM that may produce or abet AD development,
and normoinsulinemic non-diabetic AD. Accordingly,
the development of agents that diminish aPKC activity
directly or indirectly may provide new approaches for
preventing or treating various forms of AD and other
dementias. This idea urgently needs to be tested.

REFERENCES
1.

Cole SL, Vassar R. Mol Neurodegener. 2007; 2:22.
https://doi.org/10.1186/1750‐1326‐2‐22

2.

Sajan M, et al. Diabetes. 2016; 65:1892–903.
https://doi.org/10.2337/db15‐1428

3.

Sajan MP, et al. Neurobiol Aging. 2018; 61:225–37.
https://doi.org/10.1016/j.neurobiolaging.2017.09.001

4.

Talbot K, et al. J Clin Invest. 2012; 122:1316–38.
https://doi.org/10.1172/JCI59903

5.

Craft S, et al. J Alzheimers Dis. 2017; 57:1325–34.
https://doi.org/10.3233/JAD‐161256

Robert V. Farese: Department of Internal Medicine,
University of South Florida College of Medicine, Tampa,
FL 33612, USA
Correspondence: Robert V. Farese
Email: rfarese@hsc.usf.edu
Keywords: Alzheimer's disease, atypical PKC, beta‐
secretase, Abeta, phospho‐tau
Copyright: Farese and Sajan. This is an open‐access article
distributed under the terms of the Creative Commons
Attribution License (CC BY 3.0), which permits unrestricted
use, distribution, and reproduction in any medium,
provided the original author and source are credited
Received: October 2, 2018
Published: December 20, 2018

www.aging‐us.com

14

AGING

